Singapore, August 15, 2023 – Update on Detection of the Latest SARS-CoV-2 Variant
Credo Diagnostics Biomedical Pte Ltd is committed to the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using the BLASTn method, comparing primers and probes of the assays involving SARS-CoV-2 virus detection to all sequences listed in GISAID up till August 11th, 2023.
We are pleased to announce that the VitaPCR™ system is capable of detecting the Omicron EG.5 and its subvariants EG.5.1, and our analysis has confirmed that the performance of our SARS-CoV-2 RNA detection assays* is not impacted by the Omicron subvariant EG.5 and its descendent lineages.
*The SARS-CoV-2 RNA detection assays include:
．VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
．VitaPCR™ SARS-CoV-2 Assay (PCRAE0114)
．VitaPCR™ SARS-CoV-2 Gen 2 Assay (PCRAE0120)
For more information, contact us at firstname.lastname@example.org.